Cargando…
Nedaplatin or Oxaliplatin Combined with Paclitaxel and Docetaxel as First-Line Treatment for Patients with Advanced Non-Small Cell Lung Cancer
BACKGROUND: Both nedaplatin and oxaliplatin combined with paclitaxel or docetaxel have demonstrated potent activity in advanced non-small cell lung cancer (NSCLC) patients, but there is no study comparing the difference between these 2 chemotherapy regimens. The aim of this study was to evaluate and...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285922/ https://www.ncbi.nlm.nih.gov/pubmed/25548985 http://dx.doi.org/10.12659/MSM.891318 |
_version_ | 1782351620718198784 |
---|---|
author | Zhang, Keqian Qin, Hong Pan, Feng Liu, Enqiang Liang, Houjie Ruan, Zhihua |
author_facet | Zhang, Keqian Qin, Hong Pan, Feng Liu, Enqiang Liang, Houjie Ruan, Zhihua |
author_sort | Zhang, Keqian |
collection | PubMed |
description | BACKGROUND: Both nedaplatin and oxaliplatin combined with paclitaxel or docetaxel have demonstrated potent activity in advanced non-small cell lung cancer (NSCLC) patients, but there is no study comparing the difference between these 2 chemotherapy regimens. The aim of this study was to evaluate and compare the efficacy and safety between the combination chemotherapy of nedaplatin or oxaliplatin plus paclitaxel and docetaxel in patients with advanced NSCLC. MATERIAL/METHODS: We retrospectively reviewed patients with stage III–IV unresectable NSCLC from 1 January 2010 to 31 December 2013 at Southwest Hospital. They all received nedaplatin (80 mg/m(2), nedaplatin group) or oxaliplatin (130 mg/m(2), oxaliplatin group) combined with paclitaxel (175 mg/m(2)) or docetaxel (75 mg/m(2)) as first-line treatment. RESULTS: There are 174 patients enrolled – 123 patients in the nedaplatin group and 51 patients in the oxaliplatin group. The objective response rates were 47.3% and 34.1% and the disease control rates were 87.5% and 79.5% in nedaplatin and oxaliplatin groups, respectively. The progression-free survival time was 10.4 months and 9.6 months (p=0.722) and the overall survival time was 18.5 months and 25.5 months in the nedaplatin and oxaliplatin groups, respectively (p=0.09). Total toxicity was greater in the oxaliplatin group (p=0.008), but there is no significant difference among ¾ grade adverse events between the 2 groups (P=0.595). CONCLUSIONS: The effect of nedaplatin plus paclitaxel and docetaxel is the same as oxaliplatin plus paclitaxel and docetaxel, and the toxicity of nedaplatin is well tolerate as first-line treatment for patients with advanced NSCLC. |
format | Online Article Text |
id | pubmed-4285922 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | International Scientific Literature, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-42859222015-02-26 Nedaplatin or Oxaliplatin Combined with Paclitaxel and Docetaxel as First-Line Treatment for Patients with Advanced Non-Small Cell Lung Cancer Zhang, Keqian Qin, Hong Pan, Feng Liu, Enqiang Liang, Houjie Ruan, Zhihua Med Sci Monit Clinical Research BACKGROUND: Both nedaplatin and oxaliplatin combined with paclitaxel or docetaxel have demonstrated potent activity in advanced non-small cell lung cancer (NSCLC) patients, but there is no study comparing the difference between these 2 chemotherapy regimens. The aim of this study was to evaluate and compare the efficacy and safety between the combination chemotherapy of nedaplatin or oxaliplatin plus paclitaxel and docetaxel in patients with advanced NSCLC. MATERIAL/METHODS: We retrospectively reviewed patients with stage III–IV unresectable NSCLC from 1 January 2010 to 31 December 2013 at Southwest Hospital. They all received nedaplatin (80 mg/m(2), nedaplatin group) or oxaliplatin (130 mg/m(2), oxaliplatin group) combined with paclitaxel (175 mg/m(2)) or docetaxel (75 mg/m(2)) as first-line treatment. RESULTS: There are 174 patients enrolled – 123 patients in the nedaplatin group and 51 patients in the oxaliplatin group. The objective response rates were 47.3% and 34.1% and the disease control rates were 87.5% and 79.5% in nedaplatin and oxaliplatin groups, respectively. The progression-free survival time was 10.4 months and 9.6 months (p=0.722) and the overall survival time was 18.5 months and 25.5 months in the nedaplatin and oxaliplatin groups, respectively (p=0.09). Total toxicity was greater in the oxaliplatin group (p=0.008), but there is no significant difference among ¾ grade adverse events between the 2 groups (P=0.595). CONCLUSIONS: The effect of nedaplatin plus paclitaxel and docetaxel is the same as oxaliplatin plus paclitaxel and docetaxel, and the toxicity of nedaplatin is well tolerate as first-line treatment for patients with advanced NSCLC. International Scientific Literature, Inc. 2014-12-30 /pmc/articles/PMC4285922/ /pubmed/25548985 http://dx.doi.org/10.12659/MSM.891318 Text en © Med Sci Monit, 2014 This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License |
spellingShingle | Clinical Research Zhang, Keqian Qin, Hong Pan, Feng Liu, Enqiang Liang, Houjie Ruan, Zhihua Nedaplatin or Oxaliplatin Combined with Paclitaxel and Docetaxel as First-Line Treatment for Patients with Advanced Non-Small Cell Lung Cancer |
title | Nedaplatin or Oxaliplatin Combined with Paclitaxel and Docetaxel as First-Line Treatment for Patients with Advanced Non-Small Cell Lung Cancer |
title_full | Nedaplatin or Oxaliplatin Combined with Paclitaxel and Docetaxel as First-Line Treatment for Patients with Advanced Non-Small Cell Lung Cancer |
title_fullStr | Nedaplatin or Oxaliplatin Combined with Paclitaxel and Docetaxel as First-Line Treatment for Patients with Advanced Non-Small Cell Lung Cancer |
title_full_unstemmed | Nedaplatin or Oxaliplatin Combined with Paclitaxel and Docetaxel as First-Line Treatment for Patients with Advanced Non-Small Cell Lung Cancer |
title_short | Nedaplatin or Oxaliplatin Combined with Paclitaxel and Docetaxel as First-Line Treatment for Patients with Advanced Non-Small Cell Lung Cancer |
title_sort | nedaplatin or oxaliplatin combined with paclitaxel and docetaxel as first-line treatment for patients with advanced non-small cell lung cancer |
topic | Clinical Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285922/ https://www.ncbi.nlm.nih.gov/pubmed/25548985 http://dx.doi.org/10.12659/MSM.891318 |
work_keys_str_mv | AT zhangkeqian nedaplatinoroxaliplatincombinedwithpaclitaxelanddocetaxelasfirstlinetreatmentforpatientswithadvancednonsmallcelllungcancer AT qinhong nedaplatinoroxaliplatincombinedwithpaclitaxelanddocetaxelasfirstlinetreatmentforpatientswithadvancednonsmallcelllungcancer AT panfeng nedaplatinoroxaliplatincombinedwithpaclitaxelanddocetaxelasfirstlinetreatmentforpatientswithadvancednonsmallcelllungcancer AT liuenqiang nedaplatinoroxaliplatincombinedwithpaclitaxelanddocetaxelasfirstlinetreatmentforpatientswithadvancednonsmallcelllungcancer AT lianghoujie nedaplatinoroxaliplatincombinedwithpaclitaxelanddocetaxelasfirstlinetreatmentforpatientswithadvancednonsmallcelllungcancer AT ruanzhihua nedaplatinoroxaliplatincombinedwithpaclitaxelanddocetaxelasfirstlinetreatmentforpatientswithadvancednonsmallcelllungcancer |